je.st
news
Tag: cancers
Cancer tech: reprogramming rogue cells in pancreatic cancers
2015-04-21 19:30:01| Extremetech
Researchers at the Sanford-Burnham Institute in San Diego have figured out a way to reprogram the rogue cells found in certain pancreatic cancers back into obedient cells.
Studies: Merck drug Keytruda effective against 3 cancers
2015-04-19 20:16:47| Biotech - Topix.net
One of the hot new cancer immunotherapy drugs, Merck & Co.' s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.
Tags: effective
studies
drug
cancers
New drug combats aggressive breast cancers
2015-02-04 23:01:59| Biotech - Topix.net
On February 3, the Food and Drug Administration approved a new drug that has showed promising results for women with aggressive estrogen receptor positive breast cancer . The new drug, IBRANCE , provides a new treatment strategy to halt tumor growth and extend the time before the cancer worsens.
Tags: drug
breast
aggressive
cancers
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
2014-12-18 13:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Acquisition Expands Mercks Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: company
held
solid
developing
FDA Approves Merck's HPV Vaccine, GARDASIL9, to Prevent Cancers and Other Diseases Caused by Nine HPV types Including Types that Cause About 90% of Cervical Cancer Cases
2014-12-11 23:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more